Pancreatic cancer is a difficult to diagnose and hard to treat tumor with a very poor prognosis. Often diagnosed at the metastatic stage, there are few treatment options available. Chemotherapy is the primary approach to both first- and second-line care. There is no standard of care beyond second-line. Current development for this cancer of high unmet need spans multiple mechanisms of action and targets.
Oncology Resource Group (ONCrg) is a team of expert analysts who rigorously evaluate the latest corporate reports, news, and data presentations to distill out important advances in complex therapeutic areas. Our comprehensive medical congress coverage, and continuous market surveillance put these advances into the context of an overarching competitive landscape in pancreatic cancer to help guide strategic and tactical commercial development decisions for market participants.